Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

被引：0

作者：

Ricordel, Charles

Barlesi, Fabrice

Cousin, Sophie

Cho, Byoung Chul

Calvo, Emiliano

Kim, Tae Min

Helissey, Carole

Kim, Jin-Soo

Vieito, Maria

Boni, Valentina

Ghiringhelli, Francois

Chadjaa, Mustapha

Masson, Nina

Soufflet, Christine

Gazzah, Anas

机构：

[1] CHU Rennes, Serv Pneumol, Rennes, France

[2] Aix Marseille Univ, CNRS, INSERM, CRCM,APHM,CEPCM,CLIP2, Marseille, France

[3] Inst Bergonie, Bordeaux, France

[4] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea

[5] START Madrid CIOCC, Ctr Integral Oncol Clara Campal, Madrid, Spain

[6] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[7] HIA Begin, Dept Med Oncol, Clin Res Unit, Paris, France

[8] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[9] Boramae Med Ctr, Seoul, South Korea

[10] Vall dHebron Inst Oncol, Barcelona, Spain

[11] Univ Hosp Quironsalud Madrid, NEXT Madrid, Madrid, Spain

[12] Ctr Georges Francois Leclerc, Dijon, France

[13] Sanofi, Vitry Sur Seine, France

[14] IT&M Stats, Neuilly Sur Seine, France

[15] Gustave Roussy, Dept Drug Dev DITEP, Villejuif, France

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9039

引用

页数：1